#CancerFocus
#Myeloid diversity in tumors: shaped by genes, location, and time. New review from Maria Nogales-Pons, Mariola Munárriz-Paños, Teresa Aceña-Gonzalo, & María Casanova-Acebes @casanova-acebes.bsky.social @cniostopcancer.bsky.social: rupress.org/jem/article/...

#CancerFocus #InnateImmunity
March 19, 2026 at 1:30 PM
T cell engagers emerge as a compelling therapeutic modality. New review from Baeuerle, Grieshaber-Bouyer, Sauer, and Michaelson: rupress.org/jem/article/...

#CancerFocus #TumorImmunology #TcellEngagers
January 12, 2026 at 2:30 PM
New review from Venkatesh and Fong @fredhutch.bsky.social describes how tumor-reactive CD4 T cells are functionally impaired in #cancer, including similarities/differences with CD8 T cells, and how immunotherapies can help overcome this. rupress.org/jem/article/...

#CancerFocus #Immunotherapy
August 7, 2025 at 4:15 PM
Ward, Kar, Balan, and Bhardwaj @bhardwajlab.bsky.social review how conventional type 1 #DendriticCells (cDC1s) coordinate antitumor immunity through cross-presentation, immune cell networking, and spatial organization in tumors. rupress.org/jem/article/...

#CancerFocus #Immunotherapy
June 10, 2026 at 4:45 PM
In this review, Adam, Suhail, Kuchroo, and Vignali highlight the challenges and novel approaches to developing agonistic inhibitory receptor (IR)-targeted therapies to treat #autoimmunity and inflammatory disorders.
rupress.org/jem/article/...

#CancerFocus #LymphocyteBiology
March 31, 2026 at 4:45 PM
CD4⁺ T cell dysfunction in #cancer. New review from Hrishi Venkatesh and Lawrence Fong @fredhutch.bsky.social: rupress.org/jem/article/...

#CancerFocus #TumorImmunology #Immunotherapy
August 14, 2025 at 3:16 PM
Leveraging cDC1 biology and function for enhanced #immunotherapy. New review from Ross W. Ward, Uddipan Kar, Sreekumar Balan, and Nina Bhardwaj @bhardwajlab.bsky.social (Icahn School of Medicine at Mount Sinai):
rupress.org/jem/article/...

#CancerFocus #TumorImmunology #InnateImmunity #inflammation
June 17, 2026 at 1:45 PM
In this review @jem.org, Adam, Suhail, Kuchroo, and Vignali highlight the challenges and novel approaches to developing agonistic inhibitory receptor (IR)-targeted therapies to treat #autoimmunity and inflammatory disorders.
rupress.org/jem/article/...

#CancerFocus #LymphocyteBiology
March 31, 2026 at 5:45 PM
In @jem.org, Ward, Kar, Balan, and Bhardwaj @bhardwajlab.bsky.social review how conventional type 1 #DendriticCells (cDC1s) coordinate antitumor immunity through cross-presentation, immune cell networking, and spatial organization in tumors. rupress.org/jem/article/...

#CancerFocus #Immunotherapy
June 10, 2026 at 5:02 PM
New review @jem.org by Venkatesh and Fong @fredhutch.bsky.social describes how tumor-reactive CD4 T cells are functionally impaired in #cancer, including similarities/differences with CD8 T cells, and how immunotherapies can help overcome this. rupress.org/jem/article/...
#CancerFocus #Immunotherapy
August 7, 2025 at 5:00 PM
YTHDFs as #radiotherapy checkpoints in tumor immunity. New review from Chuangyu Wen, Ralph Weichselbaum and colleagues: rupress.org/jem/article/...

#CancerFocus #TumorImmunology
June 12, 2025 at 6:47 PM